Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
Sponsor: University of Manitoba
Summary
The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.
Official title: Investigating the Adjunctive Use of B3-agonist in the Early Post-Rezum Procedure Period: A Randomized Controlled Trial
Key Details
Gender
MALE
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-08
Completion Date
2026-06
Last Updated
2025-06-12
Healthy Volunteers
Yes
Conditions
Interventions
Beta-3 agonists (Mirabegron/Myrbetriq)
Patients in this arm will receive the medication in pill form following their procedure
Placebo group post rezum
Patients in this arm will receive the placebo pill following their procedure.
Locations (1)
Men's Health Clinic Manitoba
Winnipeg, Manitoba, Canada